• Consensus Rating: Hold
  • Consensus Price Target: $9,176.44
  • Forecasted Upside: 13,166.51 %
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.32 (0.46%)

This chart shows the closing price for AZN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AstraZeneca Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AZN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AZN

Analyst Price Target is $9,176.44
▲ +13,166.51% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is $9,176.44, with a high forecast of $13,000.00 and a low forecast of $70.00. The average price target represents a 13,166.51% upside from the last price of $69.17.

This chart shows the closing price for AZN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 10 investment analysts is to hold stock in AstraZeneca. This rating has held steady since August 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/19/2022Berenberg BankLower TargetGBX 120 ➝ GBX 118Low
10/11/2022GuggenheimLower Target£120 ➝ £118Low
9/15/2022Credit Suisse GroupDowngradeOutperform ➝ NeutralLow
9/7/2022Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
8/29/2022ArgusUpgradeHold ➝ BuyLow
7/12/2022CitigroupBoost Target£105 ➝ £130N/A
6/14/2022UBS GroupDowngradeBuy ➝ NeutralHigh
5/24/2022DanskeInitiated CoverageBuyLow
5/18/2022Kepler Capital MarketsDowngradeBuy ➝ HoldMedium
4/21/2022Morgan StanleyBoost Target£102 ➝ £111High
4/14/2022BarclaysBoost Target£115 ➝ £120Low
4/8/2022Credit Suisse GroupBoost TargetGBX 9,000 ➝ £110Low
4/7/2022JPMorgan Chase & Co.Boost Target£100 ➝ £120Low
4/6/2022Deutsche Bank AktiengesellschaftBoost Target£105 ➝ £115Medium
2/28/2022Stifel NicolausInitiated CoverageBuyLow
2/24/2022SVB LeerinkBoost TargetOutperform$65.00 ➝ $70.00Low
2/11/2022DZ BankUpgradeSell ➝ HoldLow
12/12/2021SVB LeerinkReiterated RatingBuyMedium
12/7/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$54.00Low
11/29/2021Morgan StanleyReiterated RatingOverweightLow
11/22/2021Bryan, Garnier & CoDowngradeBuyLow
10/19/2021UBS GroupReiterated RatingBuyLow
10/11/2021Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
9/27/2021SVB LeerinkBoost TargetOutperform$71.00 ➝ $73.00Low
9/20/2021SVB LeerinkBoost TargetOutperform$69.00 ➝ $71.00High
9/17/2021Morgan StanleyReiterated RatingOverweightLow
8/12/2021JPMorgan Chase & Co.Initiated CoverageOverweightLow
8/9/2021Morgan StanleyInitiated CoverageOverweightLow
8/4/2021SVB LeerinkBoost TargetOutperform$63.00 ➝ $69.00Low
7/21/2021CitigroupReiterated RatingBuyLow
7/16/2021SVB LeerinkLower TargetOutperform$64.00 ➝ $63.00Low
6/17/2021UBS GroupReiterated RatingBuyLow
6/4/2021SVB LeerinkBoost TargetOutperform$63.00 ➝ $64.00Low
4/19/2021ArgusReiterated RatingBuy ➝ HoldN/A
4/12/2021ArgusDowngradeBuy ➝ HoldMedium
3/23/2021Societe GeneraleReiterated RatingBuyLow
3/18/2021Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
3/16/2021Jefferies Financial GroupUpgradeHold ➝ BuyLow
3/9/2021Berenberg BankReiterated RatingBuyLow
3/8/2021BarclaysReiterated RatingOverweightMedium
3/2/2021SVB LeerinkLower TargetOutperform$64.00 ➝ $63.00Low
2/25/2021UBS GroupUpgradeNeutral ➝ BuyMedium
1/22/2021BarclaysReiterated RatingOverweightLow
1/15/2021Berenberg BankReiterated RatingBuyLow
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuyLow
12/14/2020UBS GroupReiterated RatingPositiveHigh
12/13/2020Piper SandlerLower TargetOverweight$179.00 ➝ $175.00High
12/7/2020Morgan StanleyUpgradeEqual Weight ➝ OverweightLow
11/30/2020UBS GroupUpgradeSell ➝ NeutralMedium
11/23/2020Morgan StanleyReiterated RatingEqual WeightMedium
11/11/2020HSBCUpgradeReduce ➝ HoldLow
9/29/2020Berenberg BankInitiated CoverageBuyLow
9/23/2020Oddo BhfUpgradeReduce ➝ BuyLow
7/29/2020BarclaysReiterated RatingOverweightLow
6/24/2020Oddo BhfDowngradeBuy ➝ ReduceLow
6/10/2020CowenBoost Target$55.00 ➝ $60.00Low
6/4/2020UBS GroupReiterated RatingSellLow
5/29/2020GuggenheimReiterated RatingBuyMedium
5/29/2020SVB LeerinkBoost TargetOutperform$60.00 ➝ $65.00Low
5/6/2020Morgan StanleyReiterated RatingEqual WeightLow
5/6/2020ArgusBoost TargetBuy$54.00 ➝ $60.00Low
5/1/2020GuggenheimReiterated RatingBuyLow
4/27/2020BarclaysReiterated RatingOverweightLow
4/23/2020FIG PartnersInitiated CoverageReduceLow
4/15/2020Morgan StanleyReiterated RatingEqual WeightLow
2/28/2020CowenReiterated RatingBuy$55.00High
12/2/2019CowenReiterated RatingOutperform$48.00 ➝ $55.00Low
11/11/2019CowenReiterated RatingBuy$48.00Low
10/24/2019Liberum CapitalReiterated RatingHold ➝ HoldLow
9/3/2019DZ BankDowngradeHold ➝ SellLow
8/14/2019ArgusBoost TargetBuy$50.00Medium
4/29/2019Pareto SecuritiesUpgradeSell ➝ HoldLow
4/2/2019UBS GroupDowngradeNeutral ➝ Sell$40.73Medium
4/1/2019CowenUpgradeMarket Perform ➝ Outperform$42.00 ➝ $48.00Low
3/19/2019Main First BankReiterated RatingBuyLow
2/28/2019HSBCReiterated RatingSellMedium
2/26/2019Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
2/26/2019The Goldman Sachs GroupReiterated RatingSellLow
2/5/2019Exane BNP ParibasInitiated CoverageOutperformLow
2/5/2019BNP ParibasInitiated CoverageOutperform ➝ OutperformLow
1/15/2019BMO Capital MarketsReiterated RatingBuy$48.00Medium
12/14/2018Bank of AmericaReiterated RatingBuyLow
12/13/2018SunTrust BanksInitiated CoverageBuy$48.00Low
12/11/2018Jefferies Financial GroupReiterated RatingHold ➝ Hold$42.00Medium
12/9/2018Credit Suisse GroupReiterated RatingBuyLow
11/28/2018HSBCReiterated RatingSellLow
11/19/2018UBS GroupReiterated RatingHoldLow
11/19/2018BMO Capital MarketsReiterated RatingPositive ➝ Outperform$48.00Medium
11/19/2018InvestecDowngradeBuy ➝ HoldMedium
11/16/2018The Goldman Sachs GroupReiterated RatingSellLow
11/12/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
11/12/2018HSBCReiterated RatingSellMedium
10/23/2018Wolfe ResearchInitiated CoverageOutperformLow
10/8/2018GuggenheimInitiated CoverageBuy ➝ BuyLow
8/16/2018Jefferies Financial GroupDowngradeBuy ➝ HoldMedium
6/12/2018MorningstarReiterated RatingHoldLow
5/25/2018BMO Capital MarketsReiterated RatingBuy$41.00Low
3/22/2018BMO Capital MarketsSet TargetBuy$40.00Low
3/19/2018Jefferies Financial GroupUpgradeHold ➝ Buy$28.43 ➝ $36.70Low
2/20/2018BMO Capital MarketsSet TargetBuy$40.00Low
2/6/2018SVB LeerinkBoost TargetMarket Perform ➝ Market Perform$36.00 ➝ $38.00Medium
2/5/2018Sanford C. BernsteinBoost TargetOutperform$40.00 ➝ $42.00High
2/4/2018BMO Capital MarketsReiterated RatingBuyHigh
1/26/2018BMO Capital MarketsReiterated RatingBuy$38.00Low
1/18/2018SVB LeerinkReiterated RatingMkt Perform ➝ Market Perform$33.00 ➝ $36.00Low
1/10/2018BMO Capital MarketsSet TargetBuy$38.00Low
12/29/2017JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightLow
(Data available from 12/8/2017 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 53 positive mentions
  • 3 negative mentions
  • 11 very negative mentions
  • 11 very positive mentions
  • 38 positive mentions
  • 4 negative mentions
  • 8 very negative mentions
  • 14 very positive mentions
  • 42 positive mentions
  • 8 negative mentions
  • 14 very negative mentions
  • 12 very positive mentions
  • 45 positive mentions
  • 10 negative mentions
  • 9 very negative mentions
  • 8 very positive mentions
  • 46 positive mentions
  • 13 negative mentions
  • 7 very negative mentions
  • 11 very positive mentions
  • 40 positive mentions
  • 15 negative mentions
  • 3 very negative mentions
  • 9 very positive mentions
  • 19 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
  • 6 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 3 very negative mentions

Current Sentiment

  • 6 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
AstraZeneca logo
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $69.17
Low: $68.83
High: $69.46

50 Day Range

MA: $60.81
Low: $54.35
High: $68.85

52 Week Range

Now: $69.17
Low: $52.65
High: $71.70


2,915,548 shs

Average Volume

6,763,567 shs

Market Capitalization

$214.35 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of AstraZeneca?

The following equities research analysts have issued reports on AstraZeneca in the last year: AlphaValue, Argus, Barclays PLC, Berenberg Bank, Citigroup Inc., Credit Suisse Group AG, Danske, Deutsche Bank Aktiengesellschaft, DZ Bank AG, Guggenheim, JPMorgan Chase & Co., Kepler Capital Markets, Morgan Stanley, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, TheStreet, and UBS Group AG.
View the latest analyst ratings for AZN.

What is the current price target for AstraZeneca?

9 Wall Street analysts have set twelve-month price targets for AstraZeneca in the last year. Their average twelve-month price target is $9,176.44, suggesting a possible upside of 13,166.5%. Citigroup Inc. has the highest price target set, predicting AZN will reach $13,000.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $70.00 for AstraZeneca in the next year.
View the latest price targets for AZN.

What is the current consensus analyst rating for AstraZeneca?

AstraZeneca currently has 1 sell rating, 5 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AZN, but not buy more shares or sell existing shares.
View the latest ratings for AZN.

What other companies compete with AstraZeneca?

How do I contact AstraZeneca's investor relations team?

AstraZeneca's physical mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company's listed phone number is 442037495000 and its investor relations email address is [email protected] The official website for AstraZeneca is www.astrazeneca.com. Learn More about contacing AstraZeneca investor relations.